Loading...
Despite multiple new agents for advanced urothelial cancer, it remains a highly lethal disease with a need for additional treatment options. These investigators conducted a pharmaceutical-sponsored phase II trial of sacituzumab govitecan (SG), an antibody–drug conjugate that targets trophoblast cell surface antigen 2, a transmembrane glycoprotein highly expressed on the surface of most urothelial cancer cells.
Eligible patients had advanced urothelial cancer with progression following treatment with both platinum-based chemotherapy and an immune checkpoint inhibitor. SG was administered intravenously (10 mg/kg) on days 1 and 8 every 21 days, until progression or unacceptable toxicity. The primary endpoint was objective response rate by blind…